Comparison of 4 commercially available group B Streptococcus molecular assays using remnant rectal–vaginal enrichment broths

Research output: Contribution to journalArticle

2 Scopus citations


The incidence of neonatal Group B streptococcal (GBS) disease has significantly declined since the widespread implementation of prenatal screening of expectant mothers for urogenital and gastrointestinal tract GBS colonization. Screening methods have evolved from exclusively culture-based approaches to more rapid and highly sensitive molecular methods. We chose to evaluate the performance of 4 commercially available GBS molecular tests for detection of GBS colonization using 299 antepartum rectal–vaginal specimens submitted to our laboratory for routine GBS screening. In 97% of instances, there was agreement between all 3 systems. When testing 1, 6, and 12 samples simultaneously, all methods performed comparably, but the ARIES® GBS assay required the least total hands-on time and the illumigene® Group B Streptococcus assay required the most hands-on time.

Original languageEnglish (US)
Pages (from-to)305-308
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Issue number4
StatePublished - Aug 2018



  • Group B Streptococcus
  • Neonatal meningitis
  • Neonatal sepsis
  • Real-time PCR
  • Streptococcus agalactiae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this